These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8149947)

  • 1. Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
    Müller M; Weimann HJ; Eden G; Weber W; Michaelis K; Dilger C; Achtert G
    Eur J Drug Metab Pharmacokinet; 1993; 18(3):277-83. PubMed ID: 8149947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of pharmacokinetic interactions between moxonidine and digoxin.
    Pabst G; Weimann HJ; Weber W
    Clin Pharmacokinet; 1992 Dec; 23(6):477-81. PubMed ID: 1458765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.
    Huber M; Bolbrinker J; Kreutz R
    Clin Exp Hypertens; 2006 Oct; 28(7):631-43. PubMed ID: 17060062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food on the oral bioavailability of moxonidine.
    Theodor RA; Weimann HJ; Weber W; Müller M; Michaelis K
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):61-6. PubMed ID: 1499598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinidine does not affect the renal clearance of moxonidine.
    Wise SD; Chan C; Schaefer HG; He MM; Pouliquen IJ; Mitchell MI
    Br J Clin Pharmacol; 2002 Sep; 54(3):251-4. PubMed ID: 12236844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute bioavailability of moxonidine.
    Theodor R; Weimann HJ; Weber W; Michaelis K
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):153-9. PubMed ID: 1936074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
    Trenk D; Wagner F; Jähnchen E; Plänitz V
    J Clin Pharmacol; 1987 Dec; 27(12):988-93. PubMed ID: 3437071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and disposition of the antihypertensive agent moxonidine in humans.
    He MM; Abraham TL; Lindsay TJ; Schaefer HC; Pouliquen IJ; Payne C; Czeskis B; Shipley LA; Oliver SD; Mitchell MI
    Drug Metab Dispos; 2003 Mar; 31(3):334-42. PubMed ID: 12584161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and disposition of moxonidine in Fischer 344 rats.
    He MM; Abraham TL; Lindsay TJ; Chay SH; Czeskis BA; Shipley LA
    Drug Metab Dispos; 2000 Apr; 28(4):446-59. PubMed ID: 10725314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug interaction studies with candesartan cilexetil.
    Jonkman JH; van Lier JJ; van Heiningen PN; Lins R; Sennewald R; Högemann A
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S31-5. PubMed ID: 9331003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
    Rao N; Chou T; Ventura D; Abramowitz W
    Clin Ther; 2005 Oct; 27(10):1596-606. PubMed ID: 16330295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of renal function on clinical pharmacokinetics of moxonidine.
    Kirch W; Hutt HJ; Plänitz V
    Clin Pharmacokinet; 1988 Oct; 15(4):245-53. PubMed ID: 3191647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
    Clin Drug Investig; 2013 Dec; 33(12):929-38. PubMed ID: 24132772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tinospora cordifolia aqua-alcoholic extract on pharmacokinetic of Glibenclamide in rat: An herb-drug interaction study.
    Sahu R; Ahmed T; Sangana R; Punde R; Subudhi BB
    J Pharm Biomed Anal; 2018 Mar; 151():310-316. PubMed ID: 29413979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus.
    Mück W; Heine PR; Breuel HP; Niklaus H; Horkulak J; Ahr G
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):89-94. PubMed ID: 7757317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.